 Home > Medical News > Medical Research Articles > Gavo cel is designated by the FDA as an orphan drug for cholangiocarcinoma

Gavo cel is designated by the FDA as an orphan drug for cholangiocarcinoma

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

tumor cartoon

human gene therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Gavo-cel is a new type of cell therapy consisting of autologous genetically engineered T cells expressing a single domain antibody that recognizes human mesothelin, and fused with the CD3-ε subunit, which acts on the expressive T cell receptor.

The new clinical data from Gavo-cel's dose increase in the phase 1/2 clinical trial for the treatment of refractory mesothelin-expressing solid tumors will be highlighted as part of the oral report at the ESMO meeting in 2021

(Picture from ESMO official website)

(Picture from TCR2 official website)

Mesothelin is a cell surface glycoprotein that is highly expressed in a variety of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer and pancreatic cancer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Cholangiocarcinoma therapy Gavo-cel received FDA orphan drug designation

11-05

Related Products

Neopentyl Glycol CAS NO.126-30-7 99% High Quality Factory Supply

CAS No.: 126-30-7

Industrial Grade

$1.7-2/KG FOB

Factory Supply Tirzepatide 10 mg 15mg Weight Loss Peptide 10mg 99.9% CAS: 2023788-19-2

CAS No.: 2023788-19-2

Pharmacy Grade

$4-5/UNIT FOB

good quality 2cb wholesale

CAS No.: 58743-75-2

$2-2.2/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Gavo cel is designated by the FDA as an orphan drug for cholangiocarcinoma

Related Articles

Cholangiocarcinoma therapy Gavo-cel received FDA orphan drug designation